Last reviewed · How we verify
NCT04385212
Outcomes in Hospitalized Older Patients With COVID-19
trial in Coronavirus Infection in 230 participants. Completed in 14 April 2020.
14 April 2020
Quick facts
| Lead sponsor | University Hospital, Geneva |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 230 |
| Start date | 13 March 2020 |
| Primary completion | 14 April 2020 |
| Estimated completion | 14 April 2020 |
| Sites | 1 location across Switzerland |
Conditions studied
- Coronavirus Infection — all drugs for Coronavirus Infection →
- Sars-CoV2 — all drugs for Sars-CoV2 →
- Elderly Infection — all drugs for Elderly Infection →
- Old Age; Debility — all drugs for Old Age; Debility →
Sponsor
University Hospital, Geneva
Who can join
65 and older, any sex, with Coronavirus Infection or Sars-CoV2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In December 2019, the first patients infected with the 2019 novel coronavirus (2019-nCoV) were diagnosed in Wuhan. The clinical presentation and course of Severe Acute Respiratory Syndrome-CoV-2 (SARS-CoV-2) infection is poorly understood in older patients and is certainly different from the general population. This project is designed to better understand and to determine clinical, biological and radiological markers of poor adverse outcomes in hospitalized older patients diagnosed with COVID-19.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Prognostic Role of Subcutaneous and Visceral Adiposity in Hospitalized Octogenarians with COVID-19.
Scheffler M, Genton L, Graf CE, Remuinan J, et al · · 2021 · cited 10× · PMID 34884199 · DOI 10.3390/jcm10235500
Verify or expand the search:
- PubMed search for NCT04385212
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronavirus Infection
Currently open trials in the same condition.
- NCT04885504 — Post COVID-19 Biorepository · recruiting
- NCT04445454 — Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection · Phase 1, PHASE2 · recruiting
- NCT04510025 — Capturing MultiORgan Effects of COVID-19 · recruiting
- NCT04376034 — Convalescent Plasma Collection and Treatment in Pediatrics and Adults · Phase 3 · recruiting
Other University Hospital, Geneva trials
Trials by the same sponsor.
- NCT07506356 — Investigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 Receptors · recruiting
- NCT07267624 — EARLY Antibiotics aDAptation in Severe Pneumonia(The EARLY ADAPT Study) · NA · not yet recruiting
- NCT06710210 — Hybrid Percutaneous Coronary Intervention Combining a Bioresorbable Scaffold With Drug-coated Balloons Versus a Conventi · NA · not yet recruiting
- NCT07173348 — Hypnosis on Breathlessness Mastery in Patients With Persistent Dyspnea · NA · not yet recruiting
- NCT07129655 — Cholangitis Definition and Treatment After Kasai Hepatoportoenterostomy for Biliary Atresia: TRACK-BA Study (TRacking Ch · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04385212 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Geneva
- Last refreshed: 12 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04385212.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing